Johnson & Johnson (NYSE:JNJ) Shares Sold by Samalin Investment Counsel LLC

Samalin Investment Counsel LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,694 shares of the company’s stock after selling 180 shares during the period. Samalin Investment Counsel LLC’s holdings in Johnson & Johnson were worth $1,402,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. IFS Advisors LLC grew its holdings in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in Johnson & Johnson in the third quarter valued at approximately $35,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $32,000. Runnymede Capital Advisors Inc. acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $38,000. Finally, NewSquare Capital LLC grew its holdings in Johnson & Johnson by 145.8% in the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock valued at $42,000 after purchasing an additional 172 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on JNJ shares. Bank of America raised their price objective on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a report on Wednesday, March 5th. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Leerink Partners decreased their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Morgan Stanley decreased their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $163.40 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $393.76 billion, a P/E ratio of 24.57, a P/E/G ratio of 2.56 and a beta of 0.47. The stock’s fifty day moving average is $156.99 and its two-hundred day moving average is $156.25.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the previous year, the business earned $2.29 earnings per share. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. Johnson & Johnson’s payout ratio is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.